During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow +1.22% to 13240. S&P +1.46% to 1417. Nasdaq +1.64% to 3118.
Treasurys: 30-year -0.23%. 10-yr +0.01%. 5-yr +0.06%.
Commodities: Crude +0.22% to $107.1. Gold +1.83% to $1695.35.
Currencies: Euro +0.7% vs. dollar. Yen +0.53%. Pound -0.64%
After Hours News:
Apollo Group (APOL): FQ2 beats on all fronts. Overall revenue dipped 7.5% Y/Y, primarily due to lower enrollment at the University of Phoenix, which was partially offset by selective tuition pricing and other fee changes. For the quarter, University of Phoenix degreed enrollment dropped 12.2% to 355,800. Shares +4.8% AH.
Oclaro (OCLR) is acquiring rival optical component vendor Opnext (OPXT) in an all-stock deal that values Opnext at $1.96/share, or $177M, based on today's close. Oclaro will be issuing 0.42 shares of its stock for every Opnext share outstanding. Many have speculated the optical component market is ripe for consolidation. OCLR +2.2% AH. OPXT halted. FNSR +0.9%. NPTN and JDSU could also see volatility.
KiOR (KiOR): Q4 EPS of -$0.15 in-line. Shares +0.9% AH.
Multiband (MBND): Q4 EPS of $0.06 in-line. Revenue of $77.6M (+9.9% Y/Y). Shares +4.5% AH.
Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug for treating tardive dyskinesia failed to meet its primary endpoint, when a site featuring "inconsistent and incorrect application" of its assessment protocol was included. Without the site in question, the study showed a significant reduction in TD symptoms
KiOR (KiOR): Q4 EPS of -$0.15 in-line. Shares +0.9% AH.
Multiband (MBND): Q4 EPS of $0.06 in-line. Revenue of $77.6M (+9.9% Y/Y). Shares +4.5% AH.
Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug for treating tardive dyskinesia failed to meet its primary endpoint, when a site featuring "inconsistent and incorrect application" of its assessment protocol was included. Without the site in question, the study showed a significant reduction in TD symptoms
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
